The intricacies of living organisms are often astonishing, but how do we find breakthroughs when diseased cells exhibit tenacious resistance to traditional therapies? This peptide molecule, PNC-27, is an innovative tool designed to address this challenge. In this study, we will focus on the mechanism of action, main applications, and unique potential of PNC-27 in targeted therapy.
What is PNC-27
PNC-27 powder is a therapeutic peptide that targets diseased cells and belongs to the field of anti-cytopathic drug research, making it particularly suitable for targeted therapy. It is a uniquely structured peptide composed of a series of amino acids, exhibiting strong selectivity for diseased cells and low toxicity to normal cells. Its research focuses on developing innovative strategies to treat cytopathic diseases, especially in cell types that do not respond well to traditional therapies such as chemotherapy and radiotherapy. It is a short peptide synthesized by humans, approximately 27 amino acid residues in length. Its structural features allow it to bind and target receptors on the cell membrane of diseased cells, particularly the p53 protein on the cell surface. p53 is an important tumor suppressor gene that regulates the cell cycle, DNA repair, and apoptosis. In many cytopathic diseases, p53 gene mutations lead to loss of function, allowing diseased cells to evade normal death signals. The product specifically binds to this mutated form of p53 protein and activates a series of cell death pathways by altering its conformation, ultimately leading to apoptosis (programmed cell death) of diseased cells. The chemical structure of it is similar to that of the natural p53 protein. However, its unique amino acid sequence allows it to penetrate cell membranes and attach to p53 on the surface of cytopathic cells. Experiments have shown that it can significantly inhibit the proliferation of cytopathic cells by targeting the p53 protein on their surfaces and, to some extent, overcome the drug resistance problem that traditional therapies cannot address. Unlike traditional chemotherapy drugs, The drug has higher specificity and fewer side effects. If you are interested in PNC-27, please contact Xi'an Sonwu.
What is PNC-27 used for
PNC-27 primarily exerts its anti-cytopathic effect through interaction with the p53 protein. The p53 protein plays a crucial role in normal cells, including regulating the cell cycle, repairing DNA damage, and inducing apoptosis when cells suffer severe damage. However, in many cytopathic cells, the p53 protein is mutated or inactivated, preventing it from functioning properly in inhibiting diseased cells. This allows cytopathic cells to escape death mechanisms and promotes their growth and spread. It's mechanism of action is based on its ability to target and bind to mutated or inactivated p53 proteins. Its molecular structure resembles key regions of p53, enabling PNC-27 to bind to p53 receptors on the surface of cytopathic cells. This binding triggers a series of molecular and biological death reactions, leading to damage to tissues and causing side effects such as immunosuppression, hair loss, and nausea. PNC-27, however, primarily acts selectively on cytopathic cells carrying mutated p53, thereby reducing damage to healthy tissues and resulting in fewer side effects. Furthermore, PNC-27 also has potential efficacy against cytopathic cells that have developed resistance to conventional therapies such as chemotherapy and radiotherapy. Many cytopathic cells have gradually developed resistance to conventional therapies due to p53 mutations or deletions.
What does PNC-27 do
It is designed to selectively kill diseased cells without damaging normal cells.
Mechanism of action:
1. Targeting diseased cells via HDM-2 (MDM2): This peptide binds to HDM-2, a protein overexpressed on the surface of many diseased cells but almost absent on normal cell membranes.
2. Disrupting diseased cell membranes: Upon binding to HDM-2, PNC-27 forms transmembrane pores on the diseased cell membrane, leading to a rapid loss of cell membrane integrity.
3. Inducing in vivo cell death (necrosis): This cell membrane disruption leads to direct and rapid cell death, rather than relying on the slower apoptosis pathway.
4. P53-independent action: Although it is derived from the p53 protein sequence, it does not require functional p53 to function, and therefore may be effective against diseased cells carrying p53 mutations.
Its main significance:
It exhibits selective toxicity to diseased cells in the body.
It is effective against multiple types of diseased cells in the body (as confirmed by preclinical studies).
Compared to traditional chemotherapy, it causes less damage to normal healthy cells.
Selectivity: They typically target specific negatively charged cells or receptors on the surface of cancer cells.
Low resistance: Their mechanism of action usually involves physical destruction of cells rather than targeting specific metabolic pathways, making it more difficult for diseased cells to develop resistance.
Multifunctionality: They can be used as a single drug or to deliver other therapeutic agents.
This peptide is currently under investigation for its potential to reduce the side effects of traditional chemotherapy.
If you would like to inquire about the price of PNC-27 powder or other product information, please contact Xi'an Sonwu directly.
Email: sales@sonwu.com
Reference:https://peptidehubs.com/articles/pnc-27-how-this-peptide-selectively-targets-cancer-cells-12512.html?utm_source=chatgpt.com